Single-center Study of Gustation in Idiopathic Parkinson's Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis
Centre Hospitalier Universitaire Dijon
66 participants
May 27, 2024
INTERVENTIONAL
Conditions
Summary
The aim of the PI-PEG study is to explore the taste functions of the following 3 groups of participants: * healthy volunteers * patients with early Parkinson's disease * patients with incipient Lewy body disease. To this end, the results obtained from taste evoked potentials in each of the 3 groups of participants will be compared with each other and with different nutritional, motor and cognitive data. This study could reveal a difference in cortical processing of gustatory sensory information between patients who have had idiopathic Parkinson's disease progressing for 3 years or less, and patients who have had Lewy body disease progressing for 3 years or less. Indeed, a modification of taste evoked potentials (in terms of latencies) proportional to the degree of cerebral degeneration could be observed.
Eligibility
Inclusion Criteria19
- Healthy volunteers:
- Person who has given written consent
- Adult
- Enrolled in the national register of healthy volunteers
- Fasting \> 2 hours before PEG measurement
- Body Mass Index (BMI) \< 30 kg/m².
- No cognitive complaints and normal neurological assessment
- Patients with idiopathic Parkinson's disease:
- Person who has given written consent
- Adult
- Fasting \> 2 hours before PEG measurement
- Body Mass Index (BMI) \< 30 kg/m².
- Diagnostic criteria for established or probable IPD
- Patients with Lewy body disease:
- Person who has given written consent
- Adult
- Fasting \> 2 hours prior to PEG measurement
- Body Mass Index (BMI) \< 30 kg/m².
- Diagnostic criteria for probable or possible LBD
Exclusion Criteria11
- Non-affiliated to national health insurance
- Person under legal protection (curatorship, guardianship)
- Person subject to a court order
- Pregnant, parturient or breast-feeding women
- Major unable to give consent
- MMSE score \< 15 and/or MoCA \< 10
- Known infection with COVID-19 in the 6 months prior to inclusion
- Active smoker (\> 4 cigarettes per day on a regular basis)
- Subject with pacemaker (contraindication for bioelectrical impedancemetry)
- Diabetic (type 1 or type 2)
- Taking medication (in progress at the time of the study) that interferes with gustation
Interventions
metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
socio-demographic data, medical and family history, treatment taken
MDS-UPDRS scale PART III
MoCA and MMSE scales
anthropometric data (weight, height, BMI, waist circumference, hip circumference, android/gynoid ratio, triceps skin fold, brachial circumference), bioelectrical impedancemetry (fat mass, lean mass, water mass and bone mass)
Recording of PEGs in response to a sucrose solution and a free fatty acid solution (prepared beforehand)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06439355